Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies.
Lewy body dementia
PET imaging
dopamine deficiency
glucose metabolism
metabolic connectivity
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
07
08
2019
revised:
21
10
2019
accepted:
23
10
2019
pubmed:
17
12
2019
medline:
28
4
2021
entrez:
17
12
2019
Statut:
ppublish
Résumé
Striatal dopamine deficiency and metabolic changes are well-known phenomena in dementia with Lewy bodies and can be quantified in vivo by We used the hitherto largest study cohort of combined imaging from the European consortium to elucidate the role of both biomarkers in the pathophysiological course of dementia with Lewy bodies. We compared striatal dopamine deficiency and glucose metabolism of 84 dementia with Lewy body patients and comparable healthy controls. After normalization of data, we tested their correlation by region-of-interest-based and voxel-based methods, controlled for study center, age, sex, education, and current cognitive impairment. Metabolic connectivity was analyzed by inter-region coefficients stratified by dopamine deficiency and compared to healthy controls. There was an inverse relationship between striatal dopamine availability and relative glucose hypermetabolism, pronounced in the basal ganglia and in limbic regions. With increasing dopamine deficiency, metabolic connectivity showed strong deteriorations in distinct brain regions implicated in disease symptoms, with greatest disruptions in the basal ganglia and limbic system, coincident with the pattern of relative hypermetabolism. Relative glucose hypermetabolism and disturbed metabolic connectivity of limbic and basal ganglia circuits are metabolic correlates of dopamine deficiency in dementia with Lewy bodies. Identification of specific metabolic network alterations in patients with early dopamine deficiency may serve as an additional supporting biomarker for timely diagnosis of dementia with Lewy bodies. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
Striatal dopamine deficiency and metabolic changes are well-known phenomena in dementia with Lewy bodies and can be quantified in vivo by
OBJECTIVE
We used the hitherto largest study cohort of combined imaging from the European consortium to elucidate the role of both biomarkers in the pathophysiological course of dementia with Lewy bodies.
METHODS
We compared striatal dopamine deficiency and glucose metabolism of 84 dementia with Lewy body patients and comparable healthy controls. After normalization of data, we tested their correlation by region-of-interest-based and voxel-based methods, controlled for study center, age, sex, education, and current cognitive impairment. Metabolic connectivity was analyzed by inter-region coefficients stratified by dopamine deficiency and compared to healthy controls.
RESULTS
There was an inverse relationship between striatal dopamine availability and relative glucose hypermetabolism, pronounced in the basal ganglia and in limbic regions. With increasing dopamine deficiency, metabolic connectivity showed strong deteriorations in distinct brain regions implicated in disease symptoms, with greatest disruptions in the basal ganglia and limbic system, coincident with the pattern of relative hypermetabolism.
CONCLUSIONS
Relative glucose hypermetabolism and disturbed metabolic connectivity of limbic and basal ganglia circuits are metabolic correlates of dopamine deficiency in dementia with Lewy bodies. Identification of specific metabolic network alterations in patients with early dopamine deficiency may serve as an additional supporting biomarker for timely diagnosis of dementia with Lewy bodies. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Substances chimiques
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
595-605Subventions
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : SNF 320030_169876
Pays : International
Organisme : Velox Foundation
ID : project 1123
Pays : International
Informations de copyright
© 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Références
Barker WW, Luis CA, Kashuba A, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord 2002;16:203-212.
Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet 2015;386:1683-1697.
McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 2017;89:88-100.
Walker Z, Moreno E, Thomas A, et al. Evolution of clinical features in possible DLB depending on FP-CIT SPECT result. Neurology 2016;87:1045-1051.
Morbelli S, Chincarini A, Brendel M, et al. Metabolic patterns across core features in dementia with lewy bodies. Ann Neurol 2019;85:715-725.
Bauckneht M, Arnaldi D, Nobili F, Aarsland D, Morbelli S. New tracers and new perspectives for molecular imaging in Lewy body diseases. Curr Med Chem 2018;25:3105-3130.
McKeith I, O'Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007;6:305-313.
Jellinger KA, Attems J. Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol 2006;112:253-260.
O'Brien JT, Colloby S, Fenwick J, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004;61:919-925.
Walker Z, Jaros E, Walker RW, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 2007;78:1176-1181.
Nicastro N, Garibotto V, Allali G, Assal F, Burkhard PR. Added value of combined semi-quantitative and visual [123I]FP-CIT SPECT analyses for the diagnosis of dementia with Lewy bodies. Clin Nucl Med 2017;42:e96-e102.
Nobili F, Arbizu J, Bouwman F, et al. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain (18) F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur J Neurol 2018;25:1201-1217.
Morbelli S, Perneczky R, Drzezga A, et al. Metabolic networks underlying cognitive reserve in prodromal Alzheimer disease: a European Alzheimer disease consortium project. J Nucl Med 2013;54:894-902.
Caminiti SP, Tettamanti M, Sala A, et al. Metabolic connectomics targeting brain pathology in dementia with Lewy bodies. J Cereb Blood Flow Metab 2017;37:1311-1325.
Galvin JE, Price JL, Yan Z, Morris JC, Sheline YI. Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer disease. Neurology 2011;76:1797-1803.
Kenny ER, Blamire AM, Firbank MJ, O'Brien JT. Functional connectivity in cortical regions in dementia with Lewy bodies and Alzheimer's disease. Brain 2012;135(Pt 2):569-581.
Peraza LR, Kaiser M, Firbank M, et al. fMRI resting state networks and their association with cognitive fluctuations in dementia with Lewy bodies. Neuroimage Clin 2014;4:558-565.
Peraza LR, Colloby SJ, Deboys L, O'Brien JT, Kaiser M, Taylor JP. Regional functional synchronizations in dementia with Lewy bodies and Alzheimer's disease. Int Psychogeriatr 2016;28:1143-1151.
Schumacher J, Peraza LR, Firbank M, et al. Functional connectivity in dementia with Lewy bodies: a within- and between-network analysis. Hum Brain Mapp 2018;39:1118-1129.
Ko JH, Lee CS, Eidelberg D. Metabolic network expression in parkinsonism: clinical and dopaminergic correlations. J Cereb Blood Flow Metab 2017;37:683-693.
Schindlbeck KA, Eidelberg D. Network imaging biomarkers: insights and clinical applications in Parkinson's disease. Lancet Neurol 2018;17:629-640.
Niethammer M, Tang CC, Ma Y, et al. Parkinson's disease cognitive network correlates with caudate dopamine. Neuroimage 2013;78:204-209.
Massa F, Arnaldi D, De Cesari F, et al. Neuroimaging findings and clinical trajectories of Lewy body disease in patients with MCI. Neurobiol Aging 2019;76:9-17.
Biundo R, Weis L, Bostantjopoulou S, et al. MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. J Neural Transm (Vienna) 2016;123:431-438.
Morbelli S, Chincarini A, Brendel M, et al. Metabolic patterns across core features in dementia with Lewy bodies. Ann Neurol 2019;85:715-725.
Albert NL, Unterrainer M, Diemling M, et al. Implementation of the European multicentre database of healthy controls for [(123)I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes. Eur J Nucl Med Mol Imaging 2016;43:1315-1322.
Hammers A, Allom R, Koepp MJ, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp 2003;19:224-247.
Yakushev I, Hammers A, Fellgiebel A, et al. SPM-based count normalization provides excellent discrimination of mild Alzheimer's disease and amnestic mild cognitive impairment from healthy aging. Neuroimage 2009;44:43-50.
Brendel M, Kleinberger G, Probst F, et al. Increase of TREM2 during aging of an Alzheimer's disease mouse model is paralleled by microglial activation and amyloidosis. Front Aging Neurosci 2017;9:8.
Horwitz B, Duara R, Rapoport SI. Intercorrelations of glucose metabolic rates between brain regions: application to healthy males in a state of reduced sensory input. J Cereb Blood Flow Metab 1984;4:484-499.
Burkhardt JM, Jin X, Costa RM. Dissociable effects of dopamine on neuronal firing rate and synchrony in the dorsal striatum. Front Integr Neurosci 2009;3:28.
Plenz D, Kital ST. A basal ganglia pacemaker formed by the subthalamic nucleus and external globus pallidus. Nature 1999;400:677-682.
Chiba Y, Fujishiro H, Iseki E, Kasanuki K, Sato K. The cingulate island sign on FDG-PET vs. IMP-SPECT to assess mild cognitive impairment in Alzheimer's disease vs. dementia with Lewy bodies. J Neuroimaging 2019;29:712-720.
Celone KA, Calhoun VD, Dickerson BC, et al. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci 2006;26:10222-10231.
Borghammer P, Cumming P, Aanerud J, Gjedde A. Artefactual subcortical hyperperfusion in PET studies normalized to global mean: lessons from Parkinson's disease. Neuroimage 2009;45:249-257.
Borghammer P, Jonsdottir KY, Cumming P, et al. Normalization in PET group comparison studies-the importance of a valid reference region. Neuroimage 2008;40:529-540.
Borghammer P, Chakravarty M, Jonsdottir KY, et al. Cortical hypometabolism and hypoperfusion in Parkinson's disease is extensive: probably even at early disease stages. Brain Struct Funct 2010;214:303-317.
Ma Y, Tang C, Moeller JR, Eidelberg D. Abnormal regional brain function in Parkinson's disease: truth or fiction? NeuroImage 2009;45:260-266.
Lozza C, Marie RM, Baron JC. The metabolic substrates of bradykinesia and tremor in uncomplicated Parkinson's disease. NeuroImage 2002;17:688-699.
Gardner RC, Boxer AL, Trujillo A, et al. Intrinsic connectivity network disruption in progressive supranuclear palsy. Ann Neurol 2013;73:603-616.
Morbelli S, Drzezga A, Perneczky R, et al. Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project. Neurobiol Aging 2012;33:2533-2550.